318 related articles for article (PubMed ID: 24252302)
1. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.
Pearce SG; Thosani NC; Pan JJ
Biomark Res; 2013 Feb; 1(1):7. PubMed ID: 24252302
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
4. Pathology of nonalcoholic steatohepatitis.
Brunt EM
Hepatol Res; 2005 Oct; 33(2):68-71. PubMed ID: 16214395
[TBL] [Abstract][Full Text] [Related]
5. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Sumida Y; Nakajima A; Itoh Y
World J Gastroenterol; 2014 Jan; 20(2):475-85. PubMed ID: 24574716
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?
Arulanandan A; Loomba R
Curr Hepatol Rep; 2015 Jun; 14(2):109-118. PubMed ID: 26500833
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD.
Alkhouri N; McCullough AJ
Gastroenterol Hepatol (N Y); 2012 Oct; 8(10):661-8. PubMed ID: 24683373
[TBL] [Abstract][Full Text] [Related]
9. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
10. Diagnosis and Monitoring of Nonalcoholic Steatohepatitis: Current State and Future Directions.
Kadi D; Loomba R; Bashir MR
Radiology; 2024 Jan; 310(1):e222695. PubMed ID: 38226882
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
Papatheodoridi M; Cholongitas E
Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
[TBL] [Abstract][Full Text] [Related]
12. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
Drescher HK; Weiskirchen S; Weiskirchen R
Cells; 2019 Aug; 8(8):. PubMed ID: 31394730
[TBL] [Abstract][Full Text] [Related]
13. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?
Singh SP; Barik RK
J Clin Exp Hepatol; 2020; 10(1):88-98. PubMed ID: 32025168
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
Lee DH
Endocrinol Metab (Seoul); 2020 Jun; 35(2):243-259. PubMed ID: 32615709
[TBL] [Abstract][Full Text] [Related]
15. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease.
Jayasekera D; Hartmann P
World J Hepatol; 2023 May; 15(5):609-640. PubMed ID: 37305367
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores.
Wu Y; Yang X; Morris HL; Gurka MJ; Shenkman EA; Cusi K; Bril F; Donahoo WT
JMIR Med Inform; 2022 Jun; 10(6):e36997. PubMed ID: 35666557
[TBL] [Abstract][Full Text] [Related]
18. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
Golabi P; Sayiner M; Fazel Y; Koenig A; Henry L; Younossi ZM
Expert Rev Gastroenterol Hepatol; 2016; 10(1):63-71. PubMed ID: 26469309
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
Arora A; Sharma P
J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
[TBL] [Abstract][Full Text] [Related]
20. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease.
Bell LN; Theodorakis JL; Vuppalanchi R; Saxena R; Bemis KG; Wang M; Chalasani N
Hepatology; 2010 Jan; 51(1):111-20. PubMed ID: 19885878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
